Delivra Health Q2 Revenue Slips as E-Commerce Growth Offsets Retail Weakness

Delivra Health Brands ( (TSE:DHB) ) just unveiled an update.

Delivra Health reported weaker second-quarter fiscal 2026 results as net revenue fell 12% to $2.4 million, driven by lower Dream Water sales in the U.S. and Canada, reduced LivRelief retail and infused cream volumes, and a shift in distribution channels. Despite the revenue decline and a drop in gross margin to 40%, the company is seeing strong year-to-date e-commerce growth of 26% for Dream Water and 28% for LivRelief, while cutting expenses, and management is prioritizing stabilizing retail ordering patterns, optimizing channels and expanding high-margin direct-to-consumer and U.S. opportunities to restore consistent revenue growth.

The most recent analyst rating on (TSE:DHB) stock is a Hold with a C$0.17 price target. To see the full list of analyst forecasts on Delivra Health Brands stock, see the TSE:DHB Stock Forecast page.

Spark’s Take on TSE:DHB Stock

According to Spark, TipRanks’ AI Analyst, TSE:DHB is a Neutral.

The score is primarily held back by weak financial performance—especially recent cash burn and a return to losses—despite strong revenue growth and solid gross margins. Technicals also weigh on the rating with the stock trading below major moving averages and negative MACD. Valuation is mixed because a negative P/E reflects ongoing losses and there is no dividend yield support.

To see Spark’s full report on TSE:DHB stock, click here.

More about Delivra Health Brands

Delivra Health Brands Inc. is a Vancouver-based consumer packaged goods company operating in the health and wellness sector. Its key brands, Dream Water and LivRelief, offer products targeting sleeplessness, chronic pain and anxiety, with a growing focus on e-commerce channels and U.S. market expansion.

Average Trading Volume: 18,809

Technical Sentiment Signal: Sell

Current Market Cap: C$5.47M

For an in-depth examination of DHB stock, go to TipRanks’ Overview page.